GVR Report cover Nasal Drug Delivery Technology Market Report

Nasal Drug Delivery Technology Market Analysis Report By Therapeutic Application (Asthma, Rhinitis), By Dosage Form (Powder, Gel, Spray, Drops), By Container Type, And Segment Forecasts, 2019 - 2025

  • Report ID: GVR-2-68038-740-7
  • Number of Pages: 90
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Report Overview

The global nasal drug delivery technology market size was valued at USD 41.01 billion in 2017 and is projected to expand at a CAGR of 6.5% over the forecast period. Increasing preference for alternative mode of drug administration is one of the major factors expected to fuel the market growth during the forecast period. Growing incidence of chronic diseases is also expected to contribute to market expansion over the coming years.

U.S. nasal drug delivery technology market

According to a study published in Research and Development (RAND) Review blog in 2017, around 60% of American adults have at least one chronic condition, which results in huge spending on healthcare every year. In addition, nearly 30 million Americans live with five chronic conditions or more. Furthermore, commercialization of novel products and presence of strong product pipeline are anticipated to boost market growth. For instance, Eli Lilly and Company developed a therapeutic spray (intranasal glucagon) for the treatment of low blood sugar.

The product is under review and expected to be approved by 2019 in the U.S. and Europe regions. In addition, NATESTO, developed by Endo Pharmaceuticals Inc., received approval in 2014 for Testosterone Replacement Therapy (TRT) and was commercialized in 2015. The product is the first and only gel administered on the nose for TRT in male adults diagnosed with hypogonadism. Moreover, rising patient preference for nasal products owing to increased awareness about these products along with their efficacy and easy administration properties is anticipated to fuel the market growth.

Moreover, nasal drug delivery systems offer benefits, such as noninvasiveness and reduction in lag-time caused due to oral drug delivery. These advantages help in providing better patient comfort, which in turn, improves their adherence for the medication. According to a research led by Binghamton University, State University at New York, in August 2018, Narcan (naloxone), a single-step nasal spray, is the easiest product to deliver.

Dosage Form Insights

Based on the dosage forms, the market is categorized into nasal spray, drop, gel, and powder. Sprays led the market in 2017 owing to the increasing incidence of infections and allergic rhinitis along with growing demand for generic forms of spray drugs. According to Healthy People 2020, published by Office of Disease Prevention and Health Promotion in 2016, disparities in asthma mortality and morbidity exist, especially in minority and low-income populations, causing individuals to gravitate towards more cost-effective options.

Nasal drop segment is estimated to be the fastest-growing dosage form segment with a CAGR of 7.9% over the forecast period. This growth can be attributed to the affordability and treatment success rates of these products. Rising demand for self-administration and increasing patient compliance are also likely to augment the segment growth. In addition, availability of number of drops in the market is expected contribute to the segment growth over the coming years.

Container Type Insights

Based on container type, the nasal drug delivery systems market is segmented into pressurized and non-pressurized containers. Non-pressurized was the largest container type segment in 2017. These containers are usually found in nasal drops, powders, and gels. Growing demand for related products is expected to propel the segment over the forecast period. Furthermore, according to an article published by Intertek Group PLC, nasal drug delivery technologies enable systematical or topical drug delivery.

All these factors are expected to boost the segment growth. Pressurized container type is estimated to be the fastest-growing segment at a CAGR of 7.7% over the forecast period. These containers are mostly found in nasal sprays. High demand for nasal sprays due to increasing prevalence of chronic disease, such as asthma, diabetes, and Cardiovascular Diseases (CVDs) is anticipated to propel the segment growth.

Therapeutic Application Insights

Based on therapeutic application, the market is segmented into nasal congestion, rhinitis, asthma, and others. Asthma segment held the largest share in 2017 due to availability of effective products for the disease treatment. It is also estimated to be the fastest-growing segment with a CAGR of 7.0% during the forecast period. Increasing prevalence of asthma across the globe is estimated to boost the segment growth.

Global nasal drug delivery technology market

According to the Global Asthma Report 2018, published by Global Asthma Network, around 330 million people suffer from asthma. In addition, in 2016, the Global Burden of Disease, a special research project by the Institute for Health Metrics and Evaluation, estimated that around 420,000 died due to asthma. In 2018, according to a study published in the U.S. National Library of Medicine National Institutes of Health, the prevalence of asthma is consistently high in Korea, especially among female and elderly populations.

Regional Insights

North America led the market with a revenue share of 36.21% in 2017. This growth was attributed to increased disease prevalence coupled with consumer awareness about nasal products. According to CDC, in 2017, the number of adults with asthma aged 18 years and above in the U.S. was around 20.4 million contributing approximately 8.3% of the total population in the country. Moreover, the number of children under 18 years of age with asthma was around 6.1 million. North America will witness strong growth over the next few years due to developed economies in the region.

Asia Pacific is expected to witness the fastest CAGR of 7.5% in the coming years. This growth is mainly due to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products. In addition, the presence of key companies in this region, such as AptarGroup, Inc.; Sun Pharmaceutical Industries Ltd.; and Cipla Inc., is expected to have a positive impact on the overall market.

Key Companies & Market Share Insights

The global industry is likely to face intense competition over the forecast period owing to the presence of multinational companies. Geographical expansion, new product development, and joint ventures are some of the key strategies undertaken by key market players. For instance, in 2016, OptiNose, Inc. announced pipeline project to monitor nose-to-brain application, which is funded by Research Council of Norway for treating narcolepsy of Orexin-A using OptiNose Bi-Directional Breath Powered delivery technology.

Some of the key companies in the market are GlaxoSmithKline PLC; AstraZeneca PLC; Pfizer, Inc.; OptiNose, Inc.; Becton, Dickinson and Company; Promius Pharma, LLC; Cadila Pharmaceuticals Ltd.; B.F. Ascher & Company, Inc.; PendoPharm, Inc.; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty. Ltd.; and NAVEH Pharma Ltd.

Nasal Drug Delivery Technology Market Report Scope

Report Attribute


Market size value in 2020

USD 49.1 billion

Revenue forecast in 2025

USD 67.99 billion

Growth Rate

CAGR of 6.5% from 2018 to 2025

Base year for estimation


Historical data

2014 - 2016

Forecast period

2018 - 2025

Quantitative units

Revenue in USD billion and CAGR from 2018 to 2025

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

Segments covered

Dosage form, container type, therapeutic application, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; Japan; China; India; Brazil; Mexico; South Africa

Key companies profiled

GlaxoSmithKline PLC; AstraZeneca PLC; Pfizer, Inc.; OptiNose, Inc.; Becton, Dickinson and Company; Promius Pharma, LLC; Cadila Pharmaceuticals Ltd.; B.F. Ascher & Company, Inc.; PendoPharm, Inc.; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty. Ltd.; NAVEH Pharma Ltd.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global nasal drug delivery technology market report on the basis of dosage form, container type, therapeutic application, and region:

  • Dosage Form Outlook (Revenue, USD Billion, 2014 - 2025)

    • Spray

    • Drops

    • Gel

    • Powder

  • Container Type Outlook(Revenue, USD Billion, 2014 - 2025)

    • Pressurized

    • Non-pressurized

  • Therapeutic Application Outlook (Revenue, USD Billion, 2014 - 2025)

    • Nasal Congestion

    • Rhinitis

    • Asthma

    • Others

  • Regional Outlook (Revenue, USD Billion, 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • The U.K.

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon